How Germany’s Standard of Care Influences Clinical Trial Participation with Martin Krauss

Dovital uw gezondheid- en vitaliteitbevorderende producten
46 Bekeken

  • Bedankt! Deel het met je vrienden!

    Je vind deze video niet leuk. Bedankt voor je feedback!

Med4Pets
Carlo
Published
Meet Martin Krauss - the CEO of FGK Research, an expert in clinical research with a mission to advance medical treatments and improve patient outcomes. One year after their last episode together, Martin and Maya meet again to talk about the current challenges and developments in the clinical research landscape. Why is there a decline in biotechnology investments globally and how is that affecting the dynamics of the market? What are the challenges in implementing the Clinical Trial Information System (CTIS) in Europe? How is the new Medical Research Act in Germany going to increase efficiency and benefit patients?

Follow Maya Zlatanova: https://www.linkedin.com/in/mayazlatanova/
Follow Martin Krauss: https://www.linkedin.com/in/martin-krauss-460b489/

00:00 Introduction of Martin Krauss
01:43 Challenges and Decline in Investments in Clinical Research
03:24 The Challenges and Improvements of the CTIS in Europe
17:05 The Impact of the Medical Research Act in Germany
28:35 Promoting Clinical Research and Raising Awareness
33:16 Making Clinical Trials More Efficient and Cost-Effective
Log in of aanmelden om een reactie te plaatsen.
Wees de eerste die een reactie plaatst.